MediWound Ltd. - Ordinary Shares (MDWD)

Phase III readout timing and supply constraints dominate the call.

MediWound (NASDAQ:MDWD) reported lower third-quarter revenue and a wider net loss as it increased spending on its late-stage EscharEx trial, while executives said manufacturing constraints continue to limit sales of its burn treatment NexoBrid. The company expects to complete enrollment and an inte

EscharEx advances Phase III enrollment while manufacturing facility nears regulatory completion.

MediWound (NASDAQ:MDWD) reported second-quarter 2026 revenue of $3.1 million, down from $5.7 million a year earlier, as the company continued investing in its Phase III EscharEx chronic-wound program and expanded development work around its NexoBrid burn treatment. Chief Executive Officer Ofer Gone

MediWound (NASDAQ:MDWD) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call transcripts and financial

MediWound (MDWD) Q1 2026 Earnings Transcript

MediWound (NASDAQ:MDWD) reported a wider first-quarter loss and lower revenue compared with the prior-year period, while management reaffirmed its 2026 revenue outlook and said it continued to advance its EscharEx and NexoBrid programs. On the company’s earnings call, Chief Executive Officer Ofer G

MediWound (MDWD) Q4 2025 Earnings Call Transcript

MediWound's Q3 2025 results show revenue miss but a smaller-than-expected loss. The company advances its EscharEx pipeline and expands NexoBrid manufacturing.

MediWound's Q2 2025 results show mixed performance: $5.7M revenue (+43% QoQ) missed estimates, but shares rose 5% on NexoBrid growth and EscharEx progress.